NASDAQ
16.25USD
-0.42 (-2.52%)
We have scored 15 news catalysts on Novocure Ltd (NVCR) over the past 12 months. The biggest single-day move next to one of them came Jun 19, 2026, when NVCR closed −20.0%: “Accenture Investigation Initiated: SueWallSt Investigates the Officers and Directors of Accenture (ACN)”. Coverage across the window leans negative (average ticker sentiment −0.27). Most of the impact sits in price momentum and forward growth expectations.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
1.9B
P/E
—
EPS
—
Beta
1.01
52W range
9.82-21.451
Day range
15.97–16.75
Open
16.39
Prev close
16.67
Volume
777.7K
Avg volume
1.5M
Dividend
0.00
IPO
2015-10-02
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Novocure Ltd — not a sector bucket. Click an edge to see the articles that established the link.
Suppliers, customers, partners and competitors of Novocure Ltd, taken from what the news actually said about them rather than from a sector bucket. The count is how many articles established each link.
Latest scored catalyst for NVCR: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
